Daniel A. Barocas, MD, MPH, FACS, discusses adjuvant TKI therapy in patients with renal cell carcinoma at high risk of recurrence following cytoreductive nephrectomy.
Daniel A. Barocas, MD, MPH, FACS
Advertisement
Articles by Daniel A. Barocas, MD, MPH, FACS
Advertisement
Latest Updated Articles
Dr. Barocas on Adjuvant Sunitinib in Renal Cell CarcinomaPublished: January 9th 2020 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Intellia Puts Phase 3 Trials for Transthyretin Amyloidosis Gene Editing Therapy Nex-Z on Hold Following Grade 4 Liver AE
2
M. Peter Marinkovich, MD, on Integrating Gene Therapy into Clinical Practice for Dermatologists
3
Quarter Century Update: The Continued Unknowns of Cell and Gene Therapy
4
